Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imiquimod as a dermatological therapy.

Hue Tran1, Gilberto Moreno, Stephen Shumack

  • 1St George Dermatology and Skin Cancer Centre, Kogarah, Australia.

Expert Opinion on Pharmacotherapy
|March 5, 2004
PubMed
Summary

Imiquimod, an immune response modifier, effectively treats genital warts by stimulating the immune system. It also shows potential for treating various skin conditions, including skin tumors in immunocompromised patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeated convergent evolution of bradykinin mimics as defensive toxins.

Science (New York, N.Y.)·2026
Same author

Radiotherapy-A Renaissance for Skin Cancer.

The Australasian journal of dermatology·2025
Same author

Mohs Micrographic Surgery in the Australian Public Health System: A Retrospective Observational Study and Review of the Australian Literature.

The Australasian journal of dermatology·2025
Same author

Practice Guidelines for Teledermatology in Australia: 2025 Update.

The Australasian journal of dermatology·2025
Same author

Informing a Position Statement on the Use of Large Language Models and AI Scribes in Dermatology in Australia.

The Australasian journal of dermatology·2025
Same author

A venom peptide-induced Na<sub>V</sub> channel modulation mechanism involving the interplay between fixed channel charges and ionic gradients.

The Journal of biological chemistry·2024

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Imiquimod is a commercially available immune response modifier.
  • It is approved for treating human papillomavirus-induced genital warts.
  • Its therapeutic applications extend to various dermatological conditions.

Observation:

  • Imiquimod activates toll-like receptor 7 (TLR7) on immune cells.
  • This activation stimulates a T helper cell Type 1 (Th1) immune response.
  • The drug enhances the body's natural defense against viral infections and tumors.

Findings:

  • Imiquimod is effective against genital warts.
  • It shows promise in treating basal cell carcinomas, actinic keratoses, lentigo maligna, common warts, and molluscum contagiosum.
  • The drug stimulates the immune system to target virally infected and tumor cells.

Implications:

  • Imiquimod offers a novel therapeutic approach for dermatological conditions.
  • It represents a significant advancement in immune-based therapies.
  • Further research into imiquimod and its analogues could lead to new prophylactic treatments for skin tumors, particularly in immunocompromised individuals.

Related Experiment Videos